John Jesitus

John Jesitus is a medical writer based in Westminster, CO.

Articles by John Jesitus

National report - Since no laser or light source meets every patient's needs, experts say it's crucial to choose technologies that will provide the maximum utility in a given practice setting.

National Report - Children with allergic contact dermatitis frequently react to the same allergens as adults with this condition do, according to a recent multi-center study conducted at the University of Miami and the University of Pennsylvania that calls for increased patch testing in children, especially those with chronic dermatitis.

Las Vegas - Weight-based dosing with extended-release (ER) minocycline tablets allows patients with acne to achieve efficacy equivalent to that of 2 mg/kg or 3 mg/kg of body weight daily with just 1 mg/kg daily, says James Q. Del Rosso, D.O., dermatology residency director, Valley Hospital Medical Center, Las Vegas.

Las Vegas - A skin barrier protection cream (Tetrix, Coria Laboratories) appears to reduce exposure to skin allergens and irritants and decrease symptoms of eczematous dermatitis, according to James Q. Del Rosso, D.O., dermatology residency director, Valley Hospital Medical Center, Las Vegas.

Las Vegas - Although some recent animal research and human case reports have spurred concerns regarding the safety of Botox Cosmetic (botulinum toxin A, Allergan), one of the product's pioneers says that Botox remains safe when used as directed for cosmetic indications.

To address the U.S. healthcare crisis, some dermatologists suggest everything from overhauling the FDA to abandoning it - and Medicare as it's currently configured. However, not all dermatologists agree with these proposals.

The first documented case of cutaneous polyarteritis nodosum following HPV vaccine injection suggests dermatologists should consider it as a possible vaccine-related complication, says a pathologist who worked on this case.

National report - The bankruptcy of Artes Medical, maker of the permanent facial filler ArteFill, will make it harder for permanent fillers to enter the U.S. market in the future, analysts say - although one such product, Contura's Aquamid, will likely seek Food and Drug Administration (FDA) approval in 2009.